Clinical Trials
72 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
St. Jude Children's Research Hospital
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
Milton S. Hershey Medical Center
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
University of California, San Diego
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
University of California, San Diego
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
University of Texas Southwestern Medical Center
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
University of California, San Francisco
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
University of Illinois at Chicago
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Post Transplant Donor Lymphocyte Infusion
Masonic Cancer Center, University of Minnesota
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
M.D. Anderson Cancer Center
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
St. Jude Children's Research Hospital
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Masonic Cancer Center, University of Minnesota
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Masonic Cancer Center, University of Minnesota
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Masonic Cancer Center, University of Minnesota
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
T-Cell Depleted Double UCB for Refractory AML
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
A Phase II Study of Umbilical Cord Blood Transplantation
Tufts Medical Center
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Fred Hutchinson Cancer Center
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
German CLL Study Group
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
German CLL Study Group
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center